RxDoctor Payments Data

Teresa Goebel, DO

Internal Medicine · Medina, OHNPI 1700085545

Payments from drug & device makers

$2,246in general payments, 2019–2025

Across 113 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$358
  • Merck$280
  • Pfizer$188
  • E.r. Squibb & Sons, L.L.C.$187
  • Gilead$185
  • Daiichi Sankyo Inc.$160
  • plus $888 from 14 others

What the payments were for

  • Food & beverage$2,19398%
  • Education$532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,246 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$46,976
Medicare patients
231
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib39$612,405
IbrancePalbociclib41$578,393
CalquenceAcalabrutinib Maleate34$486,492
Lenalidomide33$459,381
XtandiEnzalutamide23$325,454
RevlimidLenalidomide11$190,454
VerzenioAbemaciclib12$163,498
Abiraterone Acetate64$89,917
LorbrenaLorlatinib13$88,517
XareltoRivaroxaban45$51,516
EliquisApixaban66$47,396
Exemestane48$6,390
Anastrozole391$5,924
Letrozole135$3,323
Ondansetron Hcl65$2,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Lorbrena, Eliquis$188$714,307120 claims
AstraZenecaCalquence$358$486,49234 claims
Bristol Myers SquibbRevlimid$109$190,45411 claims
Lilly USA, LLCVerzenio$136$163,49812 claims
Johnson & JohnsonXarelto$113$51,51645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Medina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →